It is a chimeric IgGκ monoclonal antibody made up of human (75%) and animals (25%) such as rats and mice.
Mechanism of Action:
Infliximab binds to human TNF-α and as a result neutralize the cytokines.
It removes the progression of damage or erosion to structure so that patient can perform functions more efficiently.
It is administered intravenously and slowly in about 2 hour’s time in doses of 3 mg/kg to 10 mg/kg. Its half life is about 9-10 days. It is distributed equally in vascular compartments.
It is not approved for therapy continuously after 6th week.
It is used in Rheumatoid arthritis and Crohn’s disease. It has been found that the combination with methotrexate is more effective.
It may cause upper respiratory tract infections, nausea and vomiting. The production of anti-infliximab antibodies have also been studied after prolonged use of infliximab. It may cause some of the reactions at the site of infusion such as fever, chill and pruritis.
Leukopenia, neutropenia and thrombocytopenia have also been found.